Consensus $540.54M. The company said, “TransMedics (TMDX) is raising its full year 2025 revenue guidance to be in the range of $565 million to $585 million, which represents 30% growth at the midpoint compared to the company’s prior year revenue. TransMedics’ full year 2025 revenue guidance as reported on February 27, 2025 was previously in the range of $530 million to $552 million.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics Group options imply 14.5% move in share price post-earnings
- TransMedics price target raised to $105 from $90 at Piper Sandler
- TransMedics Group’s OCS Drives Structural Transformation in Liver Transplantation with Increased DCD Liver Utilization
- TransMedics Group: Strong Buy Rating Amidst Robust DCD Market Performance and Growth Prospects
- TransMedics Group: Strong Market Position and Growth Potential Justify Buy Rating